Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
Proportion of subjects who are responders at Week 6.
Secondary Outcome Measures
- Proportion of subjects with response at other timepoints. - Proportion of subjects in remission. - Average rate of response for the CDAI score. - Mean change from baseline in CDAI score Improvement in Quality of Life.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic assessment including histology.
CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening.
CRP (C-Reactive Protein) level of >4mg at screening.
Significantly abnormal laboratory tests or ECG (electrocardiogram) results.
Current use of an elemental diet or parenteral nutrition.
Clinically significant positive stool culture.
Ongoing neoplastic disease of the bowel.
Bowel perforation other than fistulae.
Has an ileostomy or colostomy.
Fixed symptomatic gastrointestinal (GI) stricture within 6 months or obstructive symptoms within 3 months of screening.
Any bowel resection within 12 months of screening or bowel resection without subsequent demonstration of recurrence of active CD.
More than 100cm of bowel resected.
Non-curative bowel surgery with 2 months of screening.
Symptoms attributed to short bowel syndrome.
Uncontrolled bacterial, viral, or fungal infection or congenital or acquired immunodeficiency.
Women who are pregnant, breast feeding, or planning to become pregnant during the study.
Less than or equal to 20mg/day oral corticosteroids for at least 4 weeks prior to screening and on stable doses for 2 weeks prior to screening.
Azathioprine and 6-MP (6-Mercaptopurine) stable dose for 3 months prior to screening.
5-ASA (5-Aminosalicylic acid) stable dose for 1 month prior to screening.
Greater than 20mg/day oral corticosteroids, or systemic intravenous corticosteroids, or antibiotics as a treatment for CD within 4 weeks prior to screening.
Cyclosporine or methotrexate during the 2 months prior to screening.
Infliximab or other biological treatments within 3 months prior to screening.